DiaMedica Therapeutics to Attend Jefferies Global Healthcare Conference in London
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy DMAC?
Source: Newsfilter
Company Participation: DiaMedica Therapeutics Inc. will have its President and CEO, Rick Pauls, participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025, where he will deliver a corporate presentation and engage in one-on-one investor meetings.
Presentation Details: The corporate presentation is scheduled for November 20, 2025, from 10:00 to 10:25 AM GMT.
Company Focus: DiaMedica is a clinical-stage biopharmaceutical company dedicated to developing treatments for serious conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke.
Lead Candidate: The company's lead candidate, DM199, is the first synthetic form of the KLK1 protein being clinically studied in the U.S. for acute ischemic stroke, with established therapeutic use in China.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DMAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DMAC
Wall Street analysts forecast DMAC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.770
Low
12.00
Averages
17.00
High
25.00
Current: 6.770
Low
12.00
Averages
17.00
High
25.00
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DiaMedica Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: DiaMedica's DM199 Phase II trial for preeclampsia in South Africa shows statistically significant reductions in blood pressure and uterine artery pulsatility index, with no placental transfer, indicating its potential application in preeclampsia and related conditions.
- Strong Financial Position: As of December 31, 2025, the company reported $59.9 million in cash and short-term investments, which is expected to fund clinical studies and corporate operations through the end of 2027, reflecting robust financial health.
- Trial Expansion Plans: The company anticipates completing the preeclampsia expansion cohort with 12 additional patients in the first half of 2026, while also planning to initiate two new cohorts in Q2, demonstrating ongoing commitment to clinical research.
- Stroke Program Progress: DiaMedica has achieved nearly 70% enrollment of the required 200 participants for its stroke program, with guidance to complete the interim analysis by the second half of 2026, showcasing the company's execution capability and confidence in this area.
See More
DiaMedica Therapeutics Reports FY Losses
- Disappointing Earnings: DiaMedica Therapeutics reported a FY GAAP EPS of -$0.70, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position Improvement: As of December 31, 2025, the company had $59.9 million in cash and short-term investments, up from $44.1 million a year earlier, suggesting improved cash management, though ongoing losses remain a concern.
- Increased Operating Cash Usage: The net cash used in operating activities for the year ended December 31, 2025, was $29.1 million, an increase from $22.1 million in 2024, reflecting heightened pressure on operational expenditures that may affect future liquidity.
- Historical Financial Insights: Historical financial data for DiaMedica Therapeutics indicates that while cash reserves have increased, persistent losses and high operational costs could limit future growth potential.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
DiaMedica to Release Q4 Earnings on March 30
- Earnings Release Date: DiaMedica Therapeutics is set to release its Q4 earnings on March 30, with significant market attention expected, which may impact the company's stock price.
- Analyst Expectations: Analysts anticipate a quarterly loss of 18 cents per share, raising concerns about the company's profitability and potentially affecting investor confidence in the stock.
- Stock Price Movement: Ahead of the earnings report, DiaMedica's stock fell 0.9% on Friday, indicating a cautious market sentiment regarding the upcoming financial results, which may lead to short-term investor volatility.
- Market Reaction: Given the potential for the earnings report to fall short of market expectations, investors should closely monitor the results to assess the company's future financial health and its implications for stock performance.
See More
DiaMedica to Release Full-Year 2025 Financial Results on March 30
- Earnings Release Schedule: DiaMedica Therapeutics Inc. will release its full-year 2025 financial results after market close on March 30, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's future growth potential.
- Conference Call Timing: The company has scheduled a conference call for March 31, 2026, at 7:00 AM CDT, during which it will discuss financial results and provide business updates, enhancing transparency and attracting investor interest.
- Web Access Information: Investors can access the conference via a live webcast on the company's website, with a recommendation to log in 15 minutes early to ensure smooth participation, thereby enhancing engagement with investors.
- Replay Services: Following the call, the webcast will remain available on the company's website for 12 months, and a telephonic replay will be accessible until April 7, 2026, ensuring that investors who could not attend live can still obtain important information.
See More
DiaMedica Receives No Objection Letter from Health Canada to Initiate Phase 2 Study for Early-Onset Preeclampsia
- Regulatory Milestone: DiaMedica Therapeutics Inc. has received a No Objection Letter from Health Canada, allowing it to initiate the Phase 2 clinical trial of DM199 in early-onset preeclampsia in 2026, marking a significant advancement in addressing unmet medical needs in this area.
- Clinical Trial Design: The trial will evaluate the safety and tolerability of DM199 in pregnant women between 24 and 32 weeks of gestation, administered subcutaneously every three days at three different dose levels, aiming to provide new treatment options for early-onset preeclampsia patients.
- Market Demand: Recent NPR coverage highlights the urgent need for new treatments for preeclampsia, with DM199 being viewed as a promising therapeutic approach that could significantly improve maternal health outcomes if successfully developed, addressing a significant unmet medical need.
- International Expansion Plans: Following regulatory approvals, DiaMedica plans to expand the trial into the United States and the United Kingdom, enhancing its competitive position in the global market and laying the groundwork for future commercialization.
See More
DiaMedica Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: DiaMedica's DM199 Phase II trial for preeclampsia in South Africa shows statistically significant reductions in blood pressure and uterine artery pulsatility index, with no placental transfer, indicating its potential application in preeclampsia and related conditions.
- Strong Financial Position: As of December 31, 2025, the company reported $59.9 million in cash and short-term investments, which is expected to fund clinical studies and corporate operations through the end of 2027, reflecting robust financial health.
- Trial Expansion Plans: The company anticipates completing the preeclampsia expansion cohort with 12 additional patients in the first half of 2026, while also planning to initiate two new cohorts in Q2, demonstrating ongoing commitment to clinical research.
- Stroke Program Progress: DiaMedica has achieved nearly 70% enrollment of the required 200 participants for its stroke program, with guidance to complete the interim analysis by the second half of 2026, showcasing the company's execution capability and confidence in this area.
See More
DiaMedica Therapeutics Reports FY Losses
- Disappointing Earnings: DiaMedica Therapeutics reported a FY GAAP EPS of -$0.70, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position Improvement: As of December 31, 2025, the company had $59.9 million in cash and short-term investments, up from $44.1 million a year earlier, suggesting improved cash management, though ongoing losses remain a concern.
- Increased Operating Cash Usage: The net cash used in operating activities for the year ended December 31, 2025, was $29.1 million, an increase from $22.1 million in 2024, reflecting heightened pressure on operational expenditures that may affect future liquidity.
- Historical Financial Insights: Historical financial data for DiaMedica Therapeutics indicates that while cash reserves have increased, persistent losses and high operational costs could limit future growth potential.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
DiaMedica to Release Q4 Earnings on March 30
- Earnings Release Date: DiaMedica Therapeutics is set to release its Q4 earnings on March 30, with significant market attention expected, which may impact the company's stock price.
- Analyst Expectations: Analysts anticipate a quarterly loss of 18 cents per share, raising concerns about the company's profitability and potentially affecting investor confidence in the stock.
- Stock Price Movement: Ahead of the earnings report, DiaMedica's stock fell 0.9% on Friday, indicating a cautious market sentiment regarding the upcoming financial results, which may lead to short-term investor volatility.
- Market Reaction: Given the potential for the earnings report to fall short of market expectations, investors should closely monitor the results to assess the company's future financial health and its implications for stock performance.
See More
DiaMedica to Release Full-Year 2025 Financial Results on March 30
- Earnings Release Schedule: DiaMedica Therapeutics Inc. will release its full-year 2025 financial results after market close on March 30, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's future growth potential.
- Conference Call Timing: The company has scheduled a conference call for March 31, 2026, at 7:00 AM CDT, during which it will discuss financial results and provide business updates, enhancing transparency and attracting investor interest.
- Web Access Information: Investors can access the conference via a live webcast on the company's website, with a recommendation to log in 15 minutes early to ensure smooth participation, thereby enhancing engagement with investors.
- Replay Services: Following the call, the webcast will remain available on the company's website for 12 months, and a telephonic replay will be accessible until April 7, 2026, ensuring that investors who could not attend live can still obtain important information.
See More
DiaMedica Receives No Objection Letter from Health Canada to Initiate Phase 2 Study for Early-Onset Preeclampsia
- Regulatory Milestone: DiaMedica Therapeutics Inc. has received a No Objection Letter from Health Canada, allowing it to initiate the Phase 2 clinical trial of DM199 in early-onset preeclampsia in 2026, marking a significant advancement in addressing unmet medical needs in this area.
- Clinical Trial Design: The trial will evaluate the safety and tolerability of DM199 in pregnant women between 24 and 32 weeks of gestation, administered subcutaneously every three days at three different dose levels, aiming to provide new treatment options for early-onset preeclampsia patients.
- Market Demand: Recent NPR coverage highlights the urgent need for new treatments for preeclampsia, with DM199 being viewed as a promising therapeutic approach that could significantly improve maternal health outcomes if successfully developed, addressing a significant unmet medical need.
- International Expansion Plans: Following regulatory approvals, DiaMedica plans to expand the trial into the United States and the United Kingdom, enhancing its competitive position in the global market and laying the groundwork for future commercialization.
See More
